"Cytarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
| Descriptor ID |
D003561
|
| MeSH Number(s) |
D03.383.742.680.245.453 D13.570.065.300 D13.570.685.245.453
|
| Concept/Terms |
Cytarabine- Cytarabine
- Arabinofuranosylcytosine
- Aracytidine
- Cytosine Arabinoside
- Arabinoside, Cytosine
- Arabinosylcytosine
Cytosar- Cytosar
- Cytosar-U
- Cytosar U
- CytosarU
|
Below are MeSH descriptors whose meaning is more general than "Cytarabine".
Below are MeSH descriptors whose meaning is more specific than "Cytarabine".
This graph shows the total number of publications written about "Cytarabine" by people in this website by year, and whether "Cytarabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 3 | 4 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 3 | 4 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 2 | 3 |
| 2020 | 1 | 3 | 4 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 2 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytarabine" by people in Profiles.
-
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML. Blood. 2025 Nov 20; 146(21):2608-2611.
-
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712. Pediatr Blood Cancer. 2023 12; 70(12):e30672.
-
Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine. Pediatr Hematol Oncol. 2023; 40(5):497-505.
-
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023 03; 98(3):E53-E56.
-
A high-pressure situation. Surv Ophthalmol. 2023 Jul-Aug; 68(4):815-820.
-
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 10; 69(10):e29812.
-
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Am J Hematol. 2022 05; 97(5):613-622.
-
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585.
-
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-?B subunit RelA. Proteomics Clin Appl. 2022 03; 16(2):e2100072.
-
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Blood Cancer Discov. 2021 Nov; 2(6):616-629.